XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
C
C

Cigna


Actualités

The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health

BRIEF-The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health Aug 12 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP FOUNDATION LAUNCHES GRANT PROGRAM TO IMPROVE VETERAN MENTAL HEALTH Source text for Eikon: ID:nPn2HqD7a Further company coverage: CI.N ( Reuters.Briefs@thomsonreuters.com )
C

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Booking Holdings, Doordash, Vertex Pharmaceuticals Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday. HIGHLIGHTS * Academy Sports and Outdoors Inc ASO.O : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Jefferies cuts target price to $4350 from $4650 * Doordash DASH.O : D.A.
A
B
C
C
C
C
E
V
E
A
B
C
C
C
C

Cigna falls after unchanged annual forecast despite profit beat

BUZZ-Cigna falls after unchanged annual forecast despite profit beat ** Shares of health insurer Cigna fall 4.8% to $331.80 ** Set for biggest one-day pct. fall since Nov. 2023 ** Co maintains its annual profit forecast after Q2 profit beat ** The lack of forecast raise despite the beat will be likely viewed as a modest disappointment - Leerink Partners ** Brokerage expects investors to keenly focus on determining if this resulted from more prudent posturing or a synthetic guide-down of the seco
C

Health insurer Cigna's cautious annual forecast spooks investors, shares fall

UPDATE 2-Health insurer Cigna's cautious annual forecast spooks investors, shares fall New throughout, adds details, background, analyst comments, updates share price By Amina Niasse and Sriparna Roy Aug 1 (Reuters) - Cigna CI.N took a cautious stance on its full-year profit outlook on Thursday despite reporting lower-than-feared medical costs in the second quarter and beating Wall Street's profit estimates, and the health insurer's shares fell more than 4%.
C

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M

Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost

Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost Aug 1 (Reuters) - Cigna CI.N reported a second-quarter profit on Thursday that beat Wall Street estimates, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit. The industry has been contending with elevated medical costs since late last year, as older adults catch up on delayed procedures, and lower-than-expected payments from the government for managing healthcare for p
C

What to Watch in the Day Ahead - Thursday, August 1

What to Watch in the Day Ahead - Thursday, August 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple is expected to report a rise in third-quarter revenue, helped by higher iPad sales from new launches and strength in its services business.
A
A
B
C
I
K
V
M
B

Humana slides on higher medical care use; other health insurers fall

BUZZ-Humana slides on higher medical care use; other health insurers fall Updates ** Shares of health insurer Humana HUM.N fall 6 .4% to $378 .63 , their biggest one-day loss pct since April ** Co reports higher-than-anticipated inpatient admissions - hospitalizations that require overnight stay - in second half of Q2 ** We continue to assess the durability of the higher admissions - HUM ** Shares of other health insurers also fall ** Shares of UnitedHealth UNH.N dip 1.2%, Elevance ELV.N down 1
C

Cigna Group <CI.N> expected to post earnings of $6.41 a share - Earnings Preview

Cigna Group expected to post earnings of $6.41 a share - Earnings Preview Cigna Group CI.N , CI is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Bloomfield Connecticut-based company is expected to report a 20.0% increase in revenue to $58.329 billion from $48.62 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
C

AbbVie lifts 2024 profit forecast, shares hit record high

UPDATE 2-AbbVie lifts 2024 profit forecast, shares hit record high Adds information from investor call throughout, updates shares in paragraph 3 By Leroy Leo and Patrick Wingrove July 25 (Reuters) - AbbVie ABBV.N increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations, sending its shares to a record high.
C

AbbVie lifts annual profit forecast on strong immunology drug sales

AbbVie lifts annual profit forecast on strong immunology drug sales July 25 (Reuters) - AbbVie ABBV.N raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter. Sales of Humira, once the world's top-selling drug, have been declining since its close copies, or biosimilars, hit the U.S.
C

Cigna Group Declares Quarterly Dividend

BRIEF-Cigna Group Declares Quarterly Dividend July 24 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP DECLARES QUARTERLY DIVIDEND CIGNA GROUP - DECLARES QUARTERLY DIVIDEND OF $1.40 PER SHARE Source text for Eikon: ID:nPn2gnfkja Further company coverage: CI.N
C

US drug industry middlemen defend business model amid accusations of raising patient costs

UPDATE 1-US drug industry middlemen defend business model amid accusations of raising patient costs Recasts with details from hearing in paragraphs 1, 4-9, 10 By Amina Niasse and Bhanvi Satija July 23 (Reuters) - U.S. pharmaceutical industry middlemen defended their role in the healthcare system during a Congressional hearing on Tuesday after committee members accused them of pushing patients toward expensive treatments even when lower-cost options are available.
C

Drug middlemen push for pricier medicines, US House committee report finds

Drug middlemen push for pricier medicines, US House committee report finds July 23 (Reuters) - U.S. pharmacy benefit managers push patients towards more expensive treatments even when lower-cost options are available, according to a report by the House Committee on Oversight and Accountability. The committee said it has found evidence that pharmacy benefit managers (PBMs) force drugmakers to pay rebates for placing their branded drugs in a favorable position on a formulary or the list of medicat
C

The Cigna Group Foundation Launches Its Health Equity Impact Fund

BRIEF-The Cigna Group Foundation Launches Its Health Equity Impact Fund July 22 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP FOUNDATION LAUNCHES ITS HEALTH EQUITY IMPACT FUND Source text for Eikon: ID:nPn9DcH8ta Further company coverage: CI.N
C

With no big deal safe, investment bankers move to safeguard fees

ANALYSIS-With no big deal safe, investment bankers move to safeguard fees Bankers push for fees on deals that regulators thwart Top banks seek up to 25% of breakup fees Fairness opinion fees rise to 20-25% of success fees By Anirban Sen NEW YORK, July 22 (Reuters) - Investment bankers are changing how they ask to be paid in a bid to preserve and boost fee revenue they generate from advising companies on mergers and acquisitions, as more big deals face challenges by regulators.
B
C
C
G
J
J
U
F

Vermont latest state to sue PBMs for allegedly driving up drug prices

Vermont latest state to sue PBMs for allegedly driving up drug prices By Brendan Pierson July 17 (Reuters) - Vermont's attorney general on Wednesday sued two of the largest U.S. pharmacy benefit managers, accusing them of driving up prescription drug prices for patients in order to enrich themselves, joining other states that have brought similar claims against the drug industry middlemen.
C

UnitedHealth gains after Q2 profit beat

BUZZ-UnitedHealth gains after Q2 profit beat Updates ** Healthcare conglomerate UnitedHealth's UNH.N shares rise 5.6% to $544.24 ** Company's Q2 profit beats, mainly due to strength in its healthcare services unit Optum ** Posts adj quarterly profit of $6.80/shr vs est $6.66 - LSEG ** Shares of other insurers also rise ** Humana HUM.N up 2.4% to $3
C
J

U.S. STOCKS Morgan Stanley, Datadog, Berkshire Hathaway

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Datadog, Berkshire Hathaway Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street jumped in upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided market sentiment.
A
A
C
G
T
U
U
D

U.S. STOCKS Health insurance firms, Super Micro, Datadog

BUZZ-U.S. STOCKS ON THE MOVE-Health insurance firms, Super Micro, Datadog Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow hit a record high in Wall Street's upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided sentiment.
A
A
C
G
H
S
T
U
U



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques